<DOC>
	<DOC>NCT02453893</DOC>
	<brief_summary>This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.</brief_summary>
	<brief_title>Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia</brief_title>
	<detailed_description>Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>men and women aged 18 to 65 years with schizophrenia; PANSS total score of at least 70 at screening and baseline; at least 2 more than 4 points in 7 of PANSSP; informed consent. allergy with iloperidone or risperidone; psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment; any other primary Axis 1 psychiatric diagnosis; a history of alcohol or drug dependence in recent 1 year; at imminent risk of harm to self or others; systolic blood pressure≤90mmHg。</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Iloperidone</keyword>
	<keyword>Risperidone</keyword>
	<keyword>PANSS</keyword>
</DOC>